Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03121001
PHASE2

Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Sponsor: University of Illinois at Chicago

View on ClinicalTrials.gov

Summary

The study is a Phase II clinical trial. Patients will receive intensity modulated total body irradiation (TBI) at a dose of 3 Gy with standard fludarabine/ i.v. cyclophosphamide conditioning prior to human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplant (HSCT). The primary objective of the study is to determine the engraftment at Day +60 following HLA-haploidentical hematopoietic stem cell transplant protocol using immunosuppressive agents and low-dose total body irradiation (TBI) for conditioning and post-transplant cyclophosphamide in patients with sickle cell disease.

Official title: A Phase II Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Key Details

Gender

All

Age Range

16 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2017-03-20

Completion Date

2026-05

Last Updated

2026-01-26

Healthy Volunteers

No

Interventions

DRUG

ATG

0.5 mg/kg IV on day -9, and 2 mg/kg on days -8 and day -7

DRUG

fludarabine

30 mg/m2 IVPB daily for day -6 (6 days before stem cell infusion) through day -2

DRUG

cyclophosphamide

14.5 mg/kg IV on days -6 and -5 and 50 mg/kg/d on days +3 and +4

RADIATION

Total body irradiation

3 Gy on day -1

PROCEDURE

Stem cell infusion

Stem cell product infused according to BMT unit policy on day 0.

DRUG

Sirolimus

loading dose of 15 mg followed by 5 mg per day on day +5

DRUG

mycophenolate mofetil

1 g every 8 h (until day 35) will be started on day 5

Locations (1)

University of Illinois at Chicago

Chicago, Illinois, United States